Relief of Ischemia in Ischemic Cardiomyopathy
PURPOSE OF THE REVIEW: Ischemic heart disease is among the most common causes of morbidity and mortality worldwide. In its stable manifestation, obstructing coronary artery stenoses prevent myocardial blood flow from matching metabolic needs of the heart under exercise conditions, which manifests clinically as dyspnea or chest pain. Prolonged bouts of ischemia may result in permanent myocardial dysfunction, heart failure, and eventually reduced survival. The aim of the present work is to review currently available approaches to provide relief of ischemia in stable coronary artery disease (CAD).
RECENT FINDINGS: Several pharmacological and interventional approaches have proven effectiveness in reducing the burden of ischemia in stable CAD and allow for symptom control and quality of life improvement. However, substantial evidence in favor of improved survival with ischemia relief is lacking, and recently published randomized controlled trial suggests that only selected groups of patients may substantially benefit from this approach. Pharmacological treatments aimed at reducing ischemia were shown to significantly reduce ischemic symptoms but failed to provide prognostic benefit. Myocardial revascularization is able to re-establish adequate coronary artery flow and was shown to improve survival in selected groups of patients, i.e., those with significant left main CAD or severe left ventricular dysfunction in multivessel CAD. Outside the previously mentioned categories, revascularization appears to improve symptoms control over medical therapy, but does not confer prognostic advantage. More studies are needed to elucidate the role of systematic invasive functional testing to identify individuals more likely to benefit from revascularization and to evaluate the prognostic role of chronic total occlusion recanalization.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
Current cardiology reports - 23(2021), 7 vom: 03. Juni, Seite 80 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Moroni, Francesco [VerfasserIn] |
---|
Links: |
---|
Themen: |
Ischemia |
---|
Anmerkungen: |
Date Completed 28.06.2021 Date Revised 07.07.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s11886-021-01520-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM326295909 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM326295909 | ||
003 | DE-627 | ||
005 | 20231225194303.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11886-021-01520-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1087.xml |
035 | |a (DE-627)NLM326295909 | ||
035 | |a (NLM)34081220 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Moroni, Francesco |e verfasserin |4 aut | |
245 | 1 | 0 | |a Relief of Ischemia in Ischemic Cardiomyopathy |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.06.2021 | ||
500 | |a Date Revised 07.07.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE OF THE REVIEW: Ischemic heart disease is among the most common causes of morbidity and mortality worldwide. In its stable manifestation, obstructing coronary artery stenoses prevent myocardial blood flow from matching metabolic needs of the heart under exercise conditions, which manifests clinically as dyspnea or chest pain. Prolonged bouts of ischemia may result in permanent myocardial dysfunction, heart failure, and eventually reduced survival. The aim of the present work is to review currently available approaches to provide relief of ischemia in stable coronary artery disease (CAD) | ||
520 | |a RECENT FINDINGS: Several pharmacological and interventional approaches have proven effectiveness in reducing the burden of ischemia in stable CAD and allow for symptom control and quality of life improvement. However, substantial evidence in favor of improved survival with ischemia relief is lacking, and recently published randomized controlled trial suggests that only selected groups of patients may substantially benefit from this approach. Pharmacological treatments aimed at reducing ischemia were shown to significantly reduce ischemic symptoms but failed to provide prognostic benefit. Myocardial revascularization is able to re-establish adequate coronary artery flow and was shown to improve survival in selected groups of patients, i.e., those with significant left main CAD or severe left ventricular dysfunction in multivessel CAD. Outside the previously mentioned categories, revascularization appears to improve symptoms control over medical therapy, but does not confer prognostic advantage. More studies are needed to elucidate the role of systematic invasive functional testing to identify individuals more likely to benefit from revascularization and to evaluate the prognostic role of chronic total occlusion recanalization | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Ischemia | |
650 | 4 | |a Ischemic cardiomyopathy | |
650 | 4 | |a Ischemic heart disease | |
650 | 4 | |a Myocardial revascularization | |
700 | 1 | |a Gertz, Zachary |e verfasserin |4 aut | |
700 | 1 | |a Azzalini, Lorenzo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current cardiology reports |d 1999 |g 23(2021), 7 vom: 03. Juni, Seite 80 |w (DE-627)NLM108756521 |x 1534-3170 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2021 |g number:7 |g day:03 |g month:06 |g pages:80 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11886-021-01520-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2021 |e 7 |b 03 |c 06 |h 80 |